Related references
Note: Only part of the references are listed.Plasma IL-8 signature correlates with pain and depressive symptomatology in patients with burning mouth syndrome: Results from a pilot study
Alison Barry et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2018)
Plasma N-acylethanolamine and endocannabinoid levels in burning mouth syndrome: Potential role in disease pathogenesis
Alison Barry et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2018)
The Relationship of Endocannabinoidome Lipid Mediators With Pain and Psychological Stress in Women With Fibromyalgia: A Case-Control Study
Niclas Stensson et al.
JOURNAL OF PAIN (2018)
The association between burning mouth syndrome and sleep disturbance: A case-control multicentre study
D. Adamo et al.
ORAL DISEASES (2018)
The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations
Stefania Petrosino et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders
Fabio Arturo Iannotti et al.
PROGRESS IN LIPID RESEARCH (2016)
Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue
Patrick McDonough et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2014)
Placebo effect in burning mouth syndrome: a systematic review
M. Kuten-Shorrer et al.
ORAL DISEASES (2014)
Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain
Stephen D. Skaper et al.
INFLAMMOPHARMACOLOGY (2014)
Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide
Paolo Ambrosino et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Palmitoylethanolamide Reduces Formalin-Induced Neuropathic-Like Behaviour Through Spinal Glial/Microglial Phenotypical Changes in Mice
Livio Luongo et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2013)
Non-Neuronal Cell Modulation Relieves Neuropathic Pain: Efficacy of the Endogenous Lipid Palmitoylethanolamide
Isabella Bettoni et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2013)
Burning Mouth Syndrome: A Review of Recent Literature
Larry Charleston
CURRENT PAIN AND HEADACHE REPORTS (2013)
Glia and Mast Cells as Targets for Palmitoylethanolamide, an Anti-inflammatory and Neuroprotective Lipid Mediator
Stephen D. Skaper et al.
MOLECULAR NEUROBIOLOGY (2013)
Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism
L. Di Cesare Mannelli et al.
MEDIATORS OF INFLAMMATION (2013)
Burning mouth syndrome
Grigoriy E. Gurvits et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Palmitoylethanolamide in the Treatment of Chronic Pain Caused by Different Etiopathogenesis
Antonio Gatti et al.
PAIN MEDICINE (2012)
Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide
Stephen D. Skaper et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2012)
Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats
Daniele De Filippis et al.
MOLECULAR PAIN (2011)
Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial
Edgardo Lopez-D'alessandro et al.
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL (2011)
Enzymological studies on the biosynthesis of N-acylethanolamines
Natsuo Ueda et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2010)
Sensory purinergic receptor P2X3 is elevated in burning mouth syndrome
Kiran Beneng et al.
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2010)
Misdiagnosed Chronic Pelvic Pain: Pudendal Neuralgia Responding to a Novel Use of Palmitoylethanolamide
Rocco Salvatore Calabro et al.
PAIN MEDICINE (2010)
The use of cognitive interviewing methodology in the design and testing of a screening tool for supportive and palliative care needs
Nisar Ahmed et al.
SUPPORTIVE CARE IN CANCER (2009)
Microglia produce and hydrolyze palmitoylethanolamide
Giulio G. Muccioli et al.
NEUROPHARMACOLOGY (2008)
The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors
Barbara Costa et al.
PAIN (2008)
Burning mouth syndrome as a trigeminal small fibre neuropathy: Increased heat and capsaicin. receptor TRPV1 in nerve fibres correlates with pain score
Z. Yilmaz et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2007)
Management of burning mouth syndrome: systematic review and management recommendations
Lauren L. Patton et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY (2007)
Gabapentin has little or no effect in the treatment of burning mouth syndrome - results of an open-label pilot study
S. M. Heckmann et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome
G Lauria et al.
PAIN (2005)
Effectiveness of gabapentin for treatment of burning mouth syndrome
TL White et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2004)
Altered dopamine D2 receptor binding in atypical facial pain
N Hagelberg et al.
PAIN (2003)
Role of the dopaminergic system in chronic pain -: a fluorodopa-PET study
SK Jääskeläinen et al.
PAIN (2001)
Share Paper
